Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) EBT Margin (2021 - 2025)

Historic EBT Margin for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Q3 2025 value amounting to 1.99%.

  • Mirum Pharmaceuticals' EBT Margin rose 173500.0% to 1.99% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.65%, marking a year-over-year increase of 232600.0%. This contributed to the annual value of 25.8% for FY2024, which is 613500.0% up from last year.
  • As of Q3 2025, Mirum Pharmaceuticals' EBT Margin stood at 1.99%, which was up 173500.0% from 4.27% recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' EBT Margin registered a high of 1825.75% during Q4 2021, and its lowest value of 941.98% during Q3 2021.
  • In the last 5 years, Mirum Pharmaceuticals' EBT Margin had a median value of 49.92% in 2023 and averaged 45.71%.
  • Data for Mirum Pharmaceuticals' EBT Margin shows a peak YoY increase of 7519200bps (in 2022) and a maximum YoY decrease of -19558000bps (in 2022) over the last 5 years.
  • Over the past 5 years, Mirum Pharmaceuticals' EBT Margin (Quarter) stood at 1825.75% in 2021, then plummeted by -107bps to 130.05% in 2022, then skyrocketed by 61bps to 50.94% in 2023, then surged by 52bps to 24.51% in 2024, then surged by 108bps to 1.99% in 2025.
  • Its last three reported values are 1.99% in Q3 2025, 4.27% for Q2 2025, and 12.23% during Q1 2025.